Clinically, expanded multicenter studies should validate SLPI expression in serum and tissue samples-including O. viverrini-infected non-malignant cohorts-to establish diagnostic thresholds distinguishing CCA from HCC. This evidence concerns the gene SLPI and hepatocellular carcinoma.